Full Breakdown
FDA Recalls of IV Saline Highlight Manufacturing Oversight Issues
9/6/2026, 3:50:32 AM
Recall Overview
The U.S. Food and Drug Administration issued five recalls of intravenous (IV) saline solutions after testing revealed fiberglass, stainless-steel fragments, and iron-oxide particles in certain lots. The recalls involve two manufacturers that supply hospitals nationwide: Baxter International and B. Braun Medical. Neither company has reported any injuries, deaths, or other adverse events linked to the affected fluids. The recalls affect patients receiving IV therapy in hospitals, home-care settings, and nursing facilities.
Timeline of Distribution and Announcements
- February 27 2026 – B. Braun began nationwide distribution of the recalled saline.
- July 31 – August 3 2026 – Baxter distributed its recalled saline to 14 states.
- August 19 2026 – B. Braun announced its first recall notice.
- August 25 2026 – Baxter announced three recall notices.
- August 27 2026 – B. Braun issued a second recall notice.
- August 28 2026 – B. Braun corrected its particle identification from zinc oxide to iron oxide (rust) in an FDA update.
Safety Guidance for Patients
Patients who may have received the recalled saline are advised to contact the hospital, infusion center, or other healthcare facility where the IV was administered to verify lot numbers. They should monitor the IV site for increasing redness, warmth, swelling, significant pain, drainage, or red streaking, especially if fever or chills develop. More serious signs—such as unexplained shortness of breath, chest pain, fainting, coughing up blood, severe weakness, or sudden neurologic symptoms—warrant immediate medical attention.
Official Statements & Responses
Robert Glatter, MD, an assistant professor of Emergency Medicine at Zucker School of Medicine and emergency physician at Northwell Health, emphasized that normal saline remains a core hospital therapy and that the recalls pertain to specific lot-quality issues rather than the inherent safety of saline. A Baxter spokesperson explained that the company detected fiberglass through its own particulate testing, which includes filtration and microscopic analysis, and is investigating root causes. B. Braun did not provide a comment to Healthline.
Verbatim Quotes
- “The broader message is not that saline has suddenly become dangerous. Normal saline remains a fundamental component of hospital care. These recalls instead highlight why sterile manufacturing, visual inspection, lot tracking and rapid removal of potentially contaminated IV products are essential patient-safety safeguards,” — Robert Glatter
- “The recent recalls concern the manufacturing quality of particular lots — not the basic safety of saline itself,” — Robert Glatter
- “For someone specifically concerned about the recall, the most useful first step is to contact the hospital, infusion center or healthcare facility where the IV was administered. The facility can determine whether the saline came from one of the recalled lots,” — Robert Glatter
- “Contact a healthcare professional if the IV site develops increasing redness, warmth, swelling, significant pain, drainage or red streaking, particularly if accompanied by fever or chills. These findings can indicate inflammation of the vein, leakage of fluid into surrounding tissue or, less commonly, infection.” — Robert Glatter
- “These symptoms have many possible causes and would be unusual after an uncomplicated IV, but they can also signal serious cardiovascular or pulmonary problems,” — Robert Glatter
